Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Minerva Neuroscie (NERV)

Minerva Neuroscie (NERV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Minerva Neurosciences: Q4 Earnings Snapshot

Minerva Neurosciences: Q4 Earnings Snapshot

NERV : 2.44 (+0.27%)
Minerva Neurosciences: Q3 Earnings Snapshot

Minerva Neurosciences: Q3 Earnings Snapshot

NERV : 2.44 (+0.27%)
Minerva Neurosciences: Q2 Earnings Snapshot

Minerva Neurosciences: Q2 Earnings Snapshot

NERV : 2.44 (+0.27%)
Bump up Your Long Term Portfolio Performance With Low Beta Stocks

In this article, discover how low beta stocks can shimmer in your portfolio!

MSFT : 406.32 (+1.82%)
NERV : 2.44 (+0.27%)
STIX : 0.3000 (-19.14%)
SERA : 10.75 (+3.97%)
TCRX : 7.32 (+0.41%)
NVCT : 6.50 (-0.15%)
Minerva Neurosciences: Q1 Earnings Snapshot

Minerva Neurosciences: Q1 Earnings Snapshot

NERV : 2.44 (+0.27%)
Minerva Neurosciences: Q4 Earnings Snapshot

Minerva Neurosciences: Q4 Earnings Snapshot

NERV : 2.44 (+0.27%)
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA

Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.

CANF : 1.9800 (+3.13%)
NERV : 2.44 (+0.27%)
AMLX : 1.7600 (-1.12%)
ACER : 0.6601 (-17.95%)
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates

EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END

CYBN.NE : 0.4750 (+3.26%)
MRVL.VN : 0.145 (+7.41%)
SAGE : 13.69 (+0.81%)
NERV : 2.44 (+0.27%)
ATAI : 1.9300 (+4.89%)
CYBN : 0.3500 (+1.16%)
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Anti-anxiety drugs are medications that are used to treat anxiety disorders that are mainly used to...

MRVL.VN : 0.145 (+7.41%)
SAGE : 13.69 (+0.81%)
NERV : 2.44 (+0.27%)
ATAI : 1.9300 (+4.89%)
CYBN : 0.3500 (+1.16%)
Minerva Neurosciences: Q3 Earnings Snapshot

Minerva Neurosciences: Q3 Earnings Snapshot

NERV : 2.44 (+0.27%)

Barchart Exclusives

FOMC, Earnings and Other Can't Miss Items This Week
This week's earnings are still a strong theme and in addition Non-Farm Payrolls, JOLTs, and the big one, The Fed Funds rate. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar